Phorte Educacional

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.


Autoria(s): Xu C.F.; Xue Z.; Bing N.; King K.S.; McCann L.A.; de Souza P.L.; Goodman V.L.; Spraggs C.F.; Mooser V.E.; Pandite L.N.
Data(s)

2012

Identificador

http://serval.unil.ch/?id=serval:BIB_968AFCD6236B

isbn:1569-8041 (Electronic)

pmid:22918879

doi:10.1093/annonc/mds249

isiid:000308017000039

Idioma(s)

en

Fonte

Annals of Oncology, vol. 23, no. 9, pp. 2470-2471

Palavras-Chave #ATP-Binding Cassette Transporters/genetics; Alanine Transaminase/blood; Anticholesteremic Agents/adverse effects; Anticholesteremic Agents/pharmacology; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacology; Clinical Trials as Topic; Drug Interactions; Drug-Induced Liver Injury/epidemiology; Drug-Induced Liver Injury/genetics; Humans; Hypercholesterolemia/blood; Hypercholesterolemia/drug therapy; Incidence; Neoplasm Proteins/genetics; Neoplasms/blood; Neoplasms/drug therapy; Polymorphism, Single Nucleotide; Pyrimidines/adverse effects; Pyrimidines/pharmacology; Reference Values; Simvastatin/adverse effects; Simvastatin/pharmacology; Sulfonamides/adverse effects; Sulfonamides/pharmacology
Tipo

info:eu-repo/semantics/article

article

Acesso ao item digital

Reportar link quebrado

Nos informe mais detalhes para melhorarmos a precisão de nossas buscas (opcional)

Biblioteca Digital

Desenvolvido por Phorte Educacional